Related Experiment Video
Updated: May 14, 2026
06:17
Osteoclast Derivation from Mouse Bone Marrow
Published on: November 6, 2014
Prostate cancer and osteoporosis
Stephen P Tuck1, Birgit Hanusch, Julie Walker
1Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Stephen.tuck@stees.nhs.uk
Current Osteoporosis Reports
|January 29, 2013
Summary
Prostate cancer treatments like androgen deprivation therapy weaken bones. Denosumab, a RANKL inhibitor, effectively reduces fractures and bone density loss in prostate cancer patients, potentially outperforming zoledronic acid.
Area of Science:
- Oncology
- Endocrinology
- Bone Metabolism
Background:
- Prostate cancer is a prevalent malignancy with increasing survival rates.
- Prostate cancer and its treatments, particularly androgen deprivation therapy (ADT), significantly increase risks of bone density loss, fractures, and skeletal-related events.
- Existing treatments like bisphosphonates show efficacy in bone loss reversal but lack anti-fracture data.
Purpose of the Study:
- To review the impact of bone density loss and fractures in prostate cancer patients.
- To evaluate the efficacy of denosumab, a RANKL inhibitor, in mitigating bone complications associated with prostate cancer and ADT.
- To compare denosumab with zoledronic acid in managing skeletal-related events.
Main Methods:
- Literature review of studies on prostate cancer, bone density, fractures, and skeletal-related events.
- Analysis of clinical trial data for bisphosphonates, zoledronic acid, and denosumab in prostate cancer patients.
- Examination of comparative studies assessing denosumab versus zoledronic acid.
Main Results:
- Androgen deprivation therapy (ADT) accelerates bone loss and increases fracture risk in prostate cancer patients.
- Denosumab has demonstrated significant increases in bone density and reductions in fracture rates.
- Both zoledronic acid and denosumab effectively reduce skeletal-related events in metastatic prostate cancer, with denosumab showing potential advantages.
Conclusions:
- Denosumab represents a promising therapeutic option for managing bone density loss and fracture risk in prostate cancer patients undergoing ADT.
- Denosumab is effective in reducing skeletal-related events and may offer superior outcomes compared to zoledronic acid.
- Further comparative studies are warranted to fully elucidate the long-term benefits and optimal use of denosumab in prostate cancer bone management.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
Related Concept Videos
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:17Hormones and Bone Tissue
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:31Osteoclasts in Bone Remodeling
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during bone...
01:20Disorders of the Male Reproductive System
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
01:40Bone Remodeling
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
01:19Psychoneuroimmunology: Diabetes and Cancer
Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...